Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

BACKGROUND: Epidermolysis bullosa (EB) is a rare genetic disorder that manifests as blistering and/or skin erosion. There is no approved treatment for EB; current standard of care consists of wound and pain management. SD-101 6% is a topical cream containing 6% allantoin that was developed for treat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Orphanet J Rare Dis
Autori principali: Paller, Amy S., Browning, John, Nikolic, Milos, Bodemer, Christine, Murrell, Dedee F., Lenon, Willistine, Krusinska, Eva, Reha, Allen, Lagast, Hjalmar, Barth, Jay A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310548/
https://ncbi.nlm.nih.gov/pubmed/32576219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-020-01419-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi